La Jolla's Giapreza lowers distributive shock mortality in Phase III

La Jolla Pharmaceutical Co. (NASDAQ:LJPC) presented data from a pre-specified analysis of the Phase III ATHOS-3 trial showing that IV Giapreza angiotensin II (formerly LJPC-501) improved the 28-day mortality rate vs. placebo in 123 patients with high severity of illness (51.8% vs. 70.8%, HR=0.62, 95% CI: 0.39, 0.98, p=0.037).

High severity of illness was defined as an Acute Physiology and Chronic Health Evaluation II (APACHE II) score of more than 30 points at baseline. Data were presented at the Society of Critical Care Medicine meeting in San Antonio...